Panzyga® (immune globulin intravenous, human - ifas) – New indication
February 12, 2021 - Pfizer announced the FDA approval of Panzyga (immune globulin intravenous, human - ifas), for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
Top